This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Saridegib

Infinity Pharmaceuticals, Inc.

Drug Names(s): IPI-926, patidegib

Description: IPI-926 is a novel, proprietary inhibitor of the Hedgehog signaling pathway. It is a derivative of the natural product cyclopamine that binds to and inhibits a key regulator of this pathway, the Smoothened receptor. The Hedgehog signaling pathway is normally active in regulating tissue and organ formation during embryonic development. However, abnormal activation of the Hedgehog pathway can lead to cancer and is believed to play a central role in allowing the proliferation and survival of several types of cancers, including pancreatic, prostate, lung, breast, and certain brain cancers.

Deal Structure: In November 2008, Infinity Pharmaceuticals entered into a global strategic alliance with Mundipharma.

Under the terms of the strategic alliance agreements, Infinity will retain U.S. commercialization rights for all oncology products developed under these programs. Infinity is obligated to pay Mundipharma a royalty on U.S. sales of these products. Mundipharma has the right to commercialize these products outside of the United States, and is obligated to pay a royalty to Infinity on sales outside of the U.S. Infinity will direct and lead all oncology discovery and development efforts on a worldwide basis.

In December 2010, Infinity and Mundipharma extended the strategic alliance to 2012. In November 2011, Infinity and Mundipharma extended the strategic alliance to 2013.

In July 2012, Infinity Pharmaceuticals announced it has restructured its strategic alliance with Mundipharma and Purdue Pharmaceutical by mutual agreement. With this restructuring, Infinity regains...See full deal structure in Biomedtracker


Saridegib News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug